← Cockpit
245_042predictionBiotech/Longevity$100T

Synthetic biology will be as diverse a market as AI (multi-trillion)

Predictor: Peter Diamandis · ep#245 "AI + Synthetic Biology: The Most Transformative Technology in Human History | Ben Lamm (Colossal)" · source

Prior probability
65.0%
Current probability
55.2%
evolves via intake + LBP
Conviction
4/5
Signal quality
A
Resolution
pending
Window
2026-04-30 – 2031-12-31
Edges in / out
5 / 0
Tickers exposed
29

Prediction text

Synthetic biology will be as diverse a market as AI (multi-trillion) | you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.

Verbatim quote

From episode "AI + Synthetic Biology: The Most Transformative Technology in Human History | Ben Lamm (Colossal)"
you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.

Resolution evidence

Status: pending

Peter synbio multi-trillion — abundance thesis, no testable timeframe.

Predictor: Peter Diamandis

κ + Brier as of 2026-05-22
κ (discount)
0.875
Brier
0.0367
excellent
Hits / Misses
10 / 0
of 15 resolved
Hit rate
66.7%
Calibration plot (stated vs observed)

Evidence about this node from Peter Diamandis is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).

Reference class

Not linked

This node isn't linked to a reference class. The Bayesian update applies without outside-view blending.

Probability over time

3 prob_history rows
0%25%50%75%100%prior 65%2026-04-302026-04-302026-05-03
intake v2milestone miss sweeplbp propagationreference class assignedlegacy v1prior_prob (analyst seed)current = 55.2%

Milestone chain

Pre-event signals (upstream prereqs + window checkpoints) → resolution event → downstream cascades. Status/dates update from linked nodes; re-derive nightly via scripts/ops/derive_milestones.py.
Leading chain: 1 fired ✓ · 6 pending
  1. 2025-12-31partialAI-in-synthetic-biology market reaches $30B in 2025 (CMI estimate)
    How: Industry research (Custom Market Insights, Grand View, MarketsandMarkets) reports AI-in-synthetic-biology market segment exceeding $30B in 2025 with >25% CAGR forecast.
    Source: Custom Market Insights — Global AI in Synthetic Biology Market Size, Share 2025-2034conf 70%
    Notes: PARTIAL — analyst estimates vary widely ($30B/$96.66M reflecting different scoping). Diamandis 'multi-trillion' is far above any 2025 forecast.
  2. 2027-05-04pendingQ1 window check-in (25%)
  3. 2026-12-31 → 2028-12-31pendingSynthetic biology total market crosses $50B annual revenue
    How: Combined synthetic biology revenue across reagents, services, and end-products (per Mordor / Grand View / Fortune Business Insights) exceeds $50B annual revenue.
    Source: Mordor Intelligence — Synthetic Biology Market Size, Analysis & Growth Report 2031conf 60%
    Notes: Required to be on 'multi-trillion' trajectory by 2031.
  4. 2026-06-01 → 2029-12-31pendingAI-designed protein / molecule receives first FDA new molecular entity approval
    How: FDA grants approval for a new molecular entity (NME) where AI-driven design is the central inventive contribution, per FDA briefing documents or sponsor press release.
    Source: Anticipated — FDA approval letters, BLA/NDA filingsconf 55%
    Notes: Required to validate that AI-powered synbio is producing real economic value, not just research output.
  5. 2028-05-07pendingQ2 window check-in (50%)
  6. 2029-05-11pendingQ3 window check-in (75%)
  7. 2027-01-01 → 2031-12-31pendingSynthetic biology firm achieves $100B+ market cap
    How: A pure-play synthetic biology / AI-bio company (e.g., Ginkgo, Recursion, Schrodinger, Isomorphic Labs, Insitro, or a successor) crosses $100B fully diluted market cap on a public exchange.
    Source: Anticipated — public exchange filingsconf 30%
    Notes: Direct equity-market test of 'multi-trillion market' thesis. As of 2026 no synbio pure-play exceeds $20B.
  8. 2030-01-01 → 2035-12-31pendingSynthetic biology revenue equals 1% of US GDP (~$300B/yr)
    How: BEA or BLS classifies a 'biofoundry / synthetic biology' NAICS subsector with revenue >$300B annually, comparable to current pharmaceuticals or autos.
    Source: Anticipated — BEA / BLS NAICS reclassificationconf 20%
    Notes: Cascade — economic-significance threshold needed to call market 'as diverse as AI'.

What if this resolves?

Clamp this prediction TRUE or FALSE and run a counterfactual Gibbs sample. Surfaces the predictions whose marginals shift most under that assumption.
(live posterior: 55%)

Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"

Evidence chain

Every probability update with full Bayesian provenance — chronological, latest first
LBP2026-05-03T02:00:01Z55.2%-1.5pp
Network propagation: 56.7% → 55.2%
6-iter LBP, residual 0.00677 · damping 0.5, w_intrinsic 0.5 · method lbp_v3 · run 1a683ac9
LBP2026-04-30T16:39:51Z56.7%-2.9pp
Network propagation: 59.6% → 56.7%
5-iter LBP, residual 0.00825 · damping 0.5, w_intrinsic 0.5 · method lbp_v2 · run 0c8a4ea3
LBP2026-04-30T02:18:57Z59.6%-5.4pp
Network propagation: 65.0% → 59.6%
5-iter LBP, residual 0.00825 · damping 0.5, w_intrinsic 0.5 · method lbp_v1 · run 592311ef

Network propagation neighbors

Top edges sorted by latest LBP cross-impact
All propagation →

Top incoming (parents)

Edges that influence THIS node's belief

KindNodeTheir probP(c|s=T)P(c|s=F)Δ implied
killerTK05
Rate Regime Persistence (10y > 5% through 2028)
30.0%0.0500.650-0.082
killerTK04
Macro Recession 2026-27 (Structural Deleveraging)
25.0%0.0500.650-0.052
killerTK12
Crypto Regulatory Kill Shot (Stablecoin Ban / BTC ETF Revers
8.0%0.0500.650+0.050
killerTK10
$100T Sovereign Debt Crisis
12.0%0.0500.650+0.026
killerTK14
Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates)
20.0%0.0500.650-0.022

Top outgoing (children)

Predictions THIS node influences

No outgoing edges.

Ticker exposure

29 ticker(s) linked

Beneficiaries (23)

SOUNCRCLIRBTRIOTMARASYMFANUYNVDABBAIGTLBAIABBNYAMZNCOINGOOGLHOODIBMMETAMSFTORCLSHOPTSLAXYZ

Adverse (5)

HYGEMBMUBTLTLQD

Prerequisites (5)

Predictions that must hit first
TypePredTitleDomainLag
killerTK05Rate Regime Persistence (10y > 5% through 2028)
killerTK04Macro Recession 2026-27 (Structural Deleveraging)
killerTK14Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates)
killerTK10$100T Sovereign Debt Crisis
killerTK12Crypto Regulatory Kill Shot (Stablecoin Ban / BTC ETF Reversal)

Dependents (0)

Predictions enabled by this
TypePredTitleDomainLag
No dependents

Expected milestones (1)

From Sheet 17 Monitoring Triggers
Expected byDescriptionStatus
2031-03-31[Biology 2031-03] [245_042] Synthetic biology will be as diverse a market as AI (multi-trillion) [235_028] Life Biosciences ER-100 Phase 1 first readout (likely late 2026/early 2027) [247_050] Virtual cell achievable through clpending

Raw metadata

From Thesis_Timeline_v1.0_FINAL workbook
{
  "nia": false,
  "qty": "Multi-trillion to $100T market",
  "url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
  "mode": "FORECAST",
  "role": "Host",
  "context": "you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.",
  "verbatim": "you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.",
  "conv_cues": "as big a diverse market",
  "direction": "NUMERIC_TARGET",
  "timeframe": "Future",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "AI-in-synthetic-biology market reaches $30B in 2025 (CMI estimate)",
      "notes": "PARTIAL — analyst estimates vary widely ($30B/$96.66M reflecting different scoping). Diamandis 'multi-trillion' is far above any 2025 forecast.",
      "source": "Custom Market Insights — Global AI in Synthetic Biology Market Size, Share 2025-2034",
      "status": "partial",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.7,
      "source_url": "https://www.custommarketinsights.com/report/al-in-synthetic-biology-market/",
      "expected_date": "2025-12-31",
      "observed_date": "2025-12-31",
      "research_origin": "deep_research",
      "measurement_criterion": "Industry research (Custom Market Insights, Grand View, MarketsandMarkets) reports AI-in-synthetic-biology market segment exceeding $30B in 2025 with >25% CAGR forecast."
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2027-05-04",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Synthetic biology total market crosses $50B annual revenue",
      "notes": "Required to be on 'multi-trillion' trajectory by 2031.",
      "source": "Mordor Intelligence — Synthetic Biology Market Size, Analysis & Growth Report 2031",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.6,
      "source_url": "https://www.mordorintelligence.com/industry-reports/synthetic-biology-market",
      "expected_date": "2027-12-31",
      "research_origin": "deep_research",
      "expected_date_range": {
        "to": "2028-12-31",
        "from": "2026-12-31"
      },
      "measurement_criterion": "Combined synthetic biology revenue across reagents, services, and end-products (per Mordor / Grand View / Fortune Business Insights) exceeds $50B annual revenue."
    },
    {
      "kind": "llm_pre_event",
      "label": "AI-designed protein / molecule receives first FDA new molecular entity approval",
      "notes": "Required to validate that AI-powered synbio is producing real economic value, not just research output.",
      "source": "Anticipated — FDA approval letters, BLA/NDA filings",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -4,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2028-03-16",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "FDA grants approval for a new molecular entity (NME) where AI-driven design is the central inventive contribution, per FDA briefing documents or sponsor press release."
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -3,
      "source_id": null,
      "expected_date": "2028-05-07",
      "observed_date": null
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q3 window check-in (75%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -2,
      "source_id": null,
      "expected_date": "2
... (truncated)